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Sin patients with valvular aortic stenosis. Second, the stepped
and sequential LVPO induced in the present study is
unlikely to completely represent the duration, pattern, and
magnitude that occur in clinical forms of LVPO. Neverthe-
less, this model of LVPO demonstrated significant pheno-
typic similarities to clinical observations of LVPO in
patients in terms of myocardial ECM remodeling and LV
diastolic dysfunction. The model system and paradigms
identified in this article may provide a means to identify
the mechanisms that give rise to pathologic ECM remodel-
ing and the potential point of irreversible ECM remodeling,
and thereby improve the timing and treatment approaches
for elimination of LVPO stimulus.
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Dr Joseph Schmoker (Burlington, Vt). I have no disclosures.
My questions pertain to the miR-1 and 133 that you studied. In
the mouse model, the transverse aortic constriction (TAC) model,
both are actually antihypertrophic and overexpression of miR-133
is associated with down-regulation of collagen in cultured fibro-
blasts. So I’m curious how you interpret this relative to the oppo-
site findings in your large animal model. In addition, did you
perform microarray analysis on myocardium to broaden your
miR phenotype?
DrYarbrough.We have just begun our initial assessments with
respect to miRs. We anticipate performing microarray analysis to
broaden the miR phenotype. I agree these initial preliminary miR
data are at odds with the relatively small amount of data that exist
in the literature with respect to this topic.
At this time, we believe that miR-133 in particular may inhibit
collagen 1A1 and 3A1. Our theory is that with up-regulation of
miR-133, there is inhibition of collagen 1A1 and 3A1 expression.
That would account for the lack of increased collagen expressionery c January 2012
Yarbrough et al Evolving Technology/Basic Sciencenoted in the study. In summary, we believe the increased collagen
content observed in the study was secondary to increased colla-
gen stability and resistance to degradation as opposed to in-
creased collagen expression. With prolongation of the animal
model, we may see a reduction in miR-133 and miR-1 levels
that will then ‘‘release’’ some of the inhibition on the collagen
1A1 and 3A1 genes. That may then lead to a robust increase
in collagen expression, counter to what we’re seeing at this point
in time at 1 month.
Dr Schmoker. My final question is related to how the control
animals were handled at the terminal data collection. My under-
standing from the article is that the controls were not violatedThe Journal of Thoracic and Cafrom the standpoint of manipulation of the heart during final
data collection. Knowing that both miR-1 and 133 can be induced
with myocardial ischemia, could subendocardial ischemia in-
curred from surgical handling and manipulation during terminal
data collection be responsible for the differences in miR expres-
sion in the experimental group relative to controls?
Dr Yarbrough. Perhaps, but I don’t believe that is likely. We
performed microsphere studies on both the control and the instru-
mented animals and showed no difference in perfusion with re-
spect to microsphere data collected from the endocardium,
myocardium, or epicardium. Thus, I don’t think submyocardial is-
chemia was likely.rdiovascular Surgery c Volume 143, Number 1 223
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